Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

9 months ago

October 19, 2025 08:00 ET  | Source: Replimune, Inc. WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc.…

RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)

9 months ago

October 19, 2025 08:00 ET  | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…

Wialon Announces Top 10 GPS Hardware Manufacturers for 2025

9 months ago

DUBAI, UAE, Oct. 19, 2025 /PRNewswire/ -- Teltonika Telematics has once again been recognized as the global leader in hardware for…

HKUST Holds Congregation 2025 Conferring Honorary Doctorates on Five Distinguished Leaders

9 months ago

HONG KONG, Oct. 18, 2025 /PRNewswire/ -- The Hong Kong University of Science and Technology (HKUST) today held its Congregation…

Landis+Gyr Awarded EcoVadis Platinum Medal for the Second Consecutive Year for Outstanding Sustainability Performance

9 months ago

CHAM, Switzerland, Oct. 16, 2025 /PRNewswire/ -- Landis+Gyr Group AG (SIX: LAND), a global leader in energy management solutions, today announced…

Kaspersky Receives Frost & Sullivan’s 2025 META Competitive Strategy Leadership Recognition in Threat Prevention

9 months ago

The company is recognized for its operational excellence, stakeholder integration, and innovation in regional threat prevention strategies across the Middle…

Redfox Cybersecurity Founder Karan Patel Announces Strategic Expansion into Hospitality with Fairfield by Marriott Mumbai Andheri West

9 months ago

The Redfox Cybersecurity Founder and His Wife Urvashi Patel Announce Their Newest Venture - Fairfield by Marriott Mumbai Andheri West,…

Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platforms Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer

9 months ago

Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

9 months ago

Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

9 months ago

 Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…